Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Delisting From Clinical Improvement in Liver Cirrhosis: A Machine Learning Decision Tree Analysis.

Transplantation·2026

Same author

Hepatic venous pressure gradient, non-invasive tests, and prognosis across the subtypes of advanced steatotic liver disease.

Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association·2026

Same author

Diagnostic innovation and models of care to improve fibrosis detection and risk stratification in steatotic liver disease.

The Lancet regional health. Europe·2026

Same author

Liver Aging Index: A Noninvasive Score for Liver Biological Aging and Liver-Related Outcomes in Multicohorts.

Aging cell·2026

Same author

Noninvasive diagnosis of clinically significant portal hypertension: current evidence and future directions.

Expert review of gastroenterology & hepatology·2026

Same author

The Natural History and Individualized Prediction of Liver Stiffness-Based Fibrosis Risk in MASLD.

Clinical and molecular hepatology·2026

Same journal

Metabolic Dysfunction-Associated Steatohepatitis: From Fibrosis-Based Risk Stratification to Emerging Therapeutic Strategies.

Clinics in liver disease·2026

Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease and Viral Hepatitis.

Clinics in liver disease·2026

Same journal

Metabolic Dysfunction Associated Steatohepatitis (MASH) in Oceania, Central America, and the Caribbean.

Clinics in liver disease·2026

Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Latin America.

Clinics in liver disease·2026

Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Africa: From Burden to Action.

Clinics in liver disease·2026

Same journal

Metabolic Dysfunction-Associated Steatotic Liver Disease in Asia: Epidemiology, Clinical Features, and Management.

Clinics in liver disease·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 18, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Published on: April 16, 2019

Noninvasive Testing for Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis.

Markos Kalligeros¹, Laurent Castera², Emmanuel A Tsochatzis³

¹Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Clinics in Liver Disease

|May 16, 2026

Summary

This summary is machine-generated.

Metabolic dysfunction-associated steatohepatitis (MASH) patients with significant fibrosis face high liver risks. Noninvasive tests can identify these high-risk individuals, guiding treatment and reducing liver biopsy needs.

Keywords:

Liver biopsy Metabolic dysfunction-associated steatohepatitis (MASH)Metabolic dysfunction-associated steatotic liver disease (MASLD)Noninvasive tests (NITs)Referral pathways Risk stratification

More Related Videos

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Related Experiment Videos

Last Updated: May 18, 2026

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis (NASH) Resolution

Published on: April 16, 2019

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis

Published on: July 18, 2025

Area of Science:

Hepatology
Gastroenterology
Noninvasive Diagnostics

Background:

Metabolic dysfunction-associated steatohepatitis (MASH) is a growing health concern.
Patients with MASH and significant fibrosis (≥F2) have a high risk of adverse liver outcomes.
Accurate detection and risk stratification are crucial for timely intervention.

Purpose of the Study:

To review noninvasive methods for detecting and risk stratifying MASH patients with fibrosis.
To identify blood-based scores, imaging tools, and combined indices for risk assessment.
To outline pathways for integrating these tests into clinical practice and reducing liver biopsy reliance.

Main Methods:

Narrative review of current literature on noninvasive tests for MASH and fibrosis.
Focus on blood-based scores, imaging techniques, and composite indices.
Analysis of cutoffs and dynamic trajectories for identifying high-risk patients.

Main Results:

Noninvasive tests offer promising alternatives to liver biopsy for MASH diagnosis and staging.
Specific blood markers and imaging modalities show efficacy in detecting fibrosis.
Combined indices may enhance predictive accuracy for adverse liver events.

Conclusions:

Noninvasive diagnostic strategies are essential for managing MASH patients with fibrosis.
Stepwise integration of these tests can optimize patient referral and treatment.
Reducing liver biopsy dependence through validated noninvasive tools is a key clinical goal.